delgocitinib
Jump to navigation
Jump to search
Indications
- moderate to severe chronic hand eczema in adults
Dosage
Adverse effects
- majority of adverse events were nonserious, mild or moderate & not related to treatment
- drug adverse effects of tyrosine kinase inhibitor(s)
- drug adverse effects of janus kinase inhibitors
Clinical trials
- phase 3 trial
More general terms
References
- ↑ Klimanskis C Positive phase 3 results reported for delgocitinib cream for chronic hand eczema. Healio. Dec 16, 2022 https://www.healio.com/news/dermatology/20221216/positive-phase-3-results-reported-for-delgocitinib-cream-for-chronic-hand-eczema
ClinicalTrials.gov Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 1). https://clinicaltrials.gov/ct2/show/NCT04871711.